Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
This collaborative nursing conference generated a positive dialogue on how the healthcare space of nursing has evolved in the past year
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
The Omicron variant doesn't escape RTPCR and RAT; States advised to ramp up testing for prompt and early identification of any cases
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
The company has has 10 existing labs in India
The funds will be used to scale up existing operations and launch new products
Rad-G is a rugged, portable, handheld Masimo SET Measure-through Motion and Low Perfusion pulse oximeter and noninvasive respiration rate monitor
Subscribe To Our Newsletter & Stay Updated